Zhejiang Cancer Hospital
404
99
107
53
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.5%
2 terminated/withdrawn out of 404 trials
96.4%
+9.9% vs industry average
15%
60 trials in Phase 3/4
8%
4 of 53 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (404)
Prevention and Treatment of Radiation-Induced Oral Mucositis in NPC With Houyanqing Oral Liquid
Role: collaborator
International Collaborative Study on AJCC/UICC TNM-10 for Nasopharyngeal Cancer
Role: collaborator
Ultra-low-dose Radiation Therapy Followed by Orelabrutinib as First-line Treatment for Stage Ⅰ-Ⅱ MALT Lymphoma: A Prospective, Multicenter Phase Ⅱ Study
Role: lead
Development of a Pan-Cancer Screening Model Based on Blood Biomarkers
Role: lead
Effect of Small Double-lumen Tube on the Intubation Time of Thoracoscopic Pulmonectomy in Asian Women
Role: lead
A Phase II Clinical Study Evaluating the Effectiveness of Injectable NC527-X in Intraoperative Imaging for Patients With Solid Tumors
Role: lead
CAR-T Combined With ASCT in the Treatment of Relapsed/Refractory Large B-cell Lymphoma With High-risk Factors.
Role: lead
Laparoscopic Staging for Stage III Gastric Cancer
Role: collaborator
Effect of Trendelenburg Positioning on Anesthesia-Induced Hypotension in Elderly Patients
Role: lead
Modified Tumor-free Techniques Operation to Cervical Cancer
Role: collaborator
A Study to Evaluate ANS014004 in Subjects With Locally Advanced or Metastatic Solid Tumors
Role: collaborator
IT-TT as an Effective and Well-Tolerated Strategy for CNS Prop in High-Risk DLBCL: a Prospective Ph II Study
Role: lead
A Hierarchical Multi-modal AI Framework for Pathological and Genetic Subtyping of Lung Cancer Based on PET/CT Imaging
Role: collaborator
A Study on the Efficacy and Safety of Switching Between Two Targeted Strategies, HP+Chemotherapy and HPy+Chemotherapy, After Treatment Progression in HER-2 Positive Advanced or Metastatic Breast Cancer
Role: lead
Disitamab Vedotin Plus Bevacizumab in HER2-Low Metastatic Breast Cancer After T-DXd Failure: A Phase II Study
Role: collaborator
Safety and Efficacy of Umbilical Cord Blood Therapy for Cancer Therapy-Induced Thrombocytopenia (CTIT)
Role: lead
A Phase II, Single-arm Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Eribulin in Pretreated Advanced Triple-negative Breast Cancer Harboring a PIK3CA Mutation
Role: collaborator
Esketamine for Prevention of Depression After Cytoreductive Surgery in Ovarian Cancer
Role: lead
Artificial Intelligence - Assisted Model for Optimal Timing of Surgery in Advanced Ovarian Cancer
Role: collaborator
Thiotepa in Combination With Pirtobrutinib (a BTK Inhibitor) and Sintilimab (a PD-1 Inhibitor) for Frail or Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma
Role: lead